Invesco
STOK icon

Invesco’s Stoke Therapeutics STOK Stock Holding History

Invesco’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.89M Sell
150,045
-109,498
-42% -$3.59M ﹤0.01% 2203
2025
Q4 		$8.24M Buy
259,543
+51,468
+25% +$1.55M ﹤0.01% 1977
2025
Q3 		$4.89M Buy
208,075
+167,868
+418% +$2.88M ﹤0.01% 2244
2025
Q2 		$456K Buy
40,207
+14,024
+54% +$133K ﹤0.01% 3195
2025
Q1 		$174K Buy
26,183
+14,118
+117% +$132K ﹤0.01% 3545
2024
Q4 		$133K Buy
+12,065
New +$148K ﹤0.01% 3587
2024
Q3 		– Sell
-437,136
Closed -$5.91M – 3878
2024
Q2 		$5.91M Buy
+437,136
New +$5.9M ﹤0.01% 2094
2022
Q2 		– Sell
-131,674
Closed -$2.77M – 4138
2022
Q1 		$2.77M Buy
+131,674
New +$2.64M ﹤0.01% 2651
2021
Q4 		– Sell
-9,325
Closed -$237K – 4101
2021
Q3 		$237K Buy
9,325
+1,323
+17% +$36.9K ﹤0.01% 3737
2021
Q2 		$269K Buy
+8,002
New +$283K ﹤0.01% 3677
2021
Q1 		– Sell
-25,329
Closed -$1.57M – 3938
2020
Q4 		$1.57M Buy
+25,329
New +$1.16M ﹤0.01% 2739

Other funds holding STOK

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Invesco's STOK Position: Q1 2026 in Review

Invesco reduced its Stoke Therapeutics (STOK) stake by 42% in Q1 2026, selling an estimated $3.59M and leaving 150,045 shares worth $4.89M. The position accounts for ﹤0.01% of the portfolio, ranked #2203.

Invesco first reported a position in STOK in Q4 2020 and has held it in 11 quarters since. The position peaked at $8.24M in Q4 2025. 196 funds tracked by Wall St. Rank hold STOK as of Q1 2026.

  • Invesco held 150,045 shares of Stoke Therapeutics worth $4.89M as of Q1 2026.
  • Invesco sold 109,498 Stoke Therapeutics shares in Q1 2026, an estimated $3.59M.
  • Stoke Therapeutics made up ﹤0.01% of Invesco's portfolio in Q1 2026, its #2203 holding.
  • Invesco first reported a position in Stoke Therapeutics in Q4 2020 and has held it in 11 quarters since.
  • Invesco's Stoke Therapeutics position peaked at $8.24M in Q4 2025.
  • 196 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q1 2026.

Based on Invesco's 13F filing for Q1 2026, filed 12 May 2026.